Clinical trials: Cancer of Pancreas
Endocrine Tumors
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
- Trial name
- CLARINET (NCT00353496)
- Testing
- lanreotide (Autogel formulation)
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 264 people
- Sponsor
- Ipsen
Pancreas Cancer
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
- Trial name
- NCT04203641
- Testing
- L-DOS47, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Helix BioPharma Corporation
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
A Single-Patient Study Using AGS 006
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional…
- Trial name
- NCT00664482
- Testing
- AGS-006
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Argos Therapeutics
Gastric Cancer, Pancreatic Cancer
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression
- Conditions
- Gastric Cancer, Pancreatic Cancer, Advanced Ovarian Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05472857
- Testing
- Claudin 18.2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 303 (NCT07491445)
- Testing
- daraxonrasib, gemcitabine, nab-paclitaxel
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.
- Trial name
- OPTIMIZE-1 (NCT04888312)
- Testing
- CD40 agonist mitazalimab in combination with chemotherapy
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 94 people
- Sponsor
- Alligator Bioscience AB
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Pancreatic Neoplasms
A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
This is a multi-center, open-label randomized phase 2 study designed to assess the progression free survival (PFS) of patients with untreatment and unresectable pancreatic cancer following treatment with either ARQ 197 or…
- Trial name
- NCT00558207
- Testing
- ARQ 197, gemcitabine
- Where
- 6 sites in Poland
- Volunteers
- 43 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
Pancreatic Cancer
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine [AG]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive…
- Trial name
- NCT07079228
- Testing
- QLS31905, Nab-paclitaxel., Gemcitabine
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.
- Trial name
- NCT02117479
- Testing
- Ruxolitinib, Capecitabine
- Where
- 230 sites in United States, Australia and 10 more
- Volunteers
- 321 people
- Sponsor
- Incyte Corporation
Pancreatic Neoplasms, Ovarian Neoplasms
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
This is a Phase 1, multicenter, open-label, dose-escalation study of DMUC4064A administered by intravenous (IV) infusion every three weeks (q3w) to cancer participants.
- Trial name
- NCT02146313
- Testing
- DMUC4064A
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Genentech, Inc.
Pancreatic Adenocarcinoma Metastatic
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
A new approach that aims to destroy pancreatic tumor cells through modification of the tumor environment. Asparagine synthetase (ASNS) is an enzyme wich synthetise asparagine.
- Trial name
- NCT02195180
- Testing
- ERY001, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- ERYtech Pharma
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Gastroenteropancreatic Neuroendocrine Tumors
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
- Trial name
- NCT02162446
- Testing
- satoreotide trizoxetan
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Ipsen
Pancreatic Cancer, Colorectal Cancer (CRC)
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has…
- Conditions
- Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
- Trial name
- NCT02955940
- Testing
- Ruxolitinib, Capecitabine, Regorafenib
- Where
- 9 sites in United States, Poland
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Pancreatic Cancer
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma
- Trial name
- NCT05494697
- Testing
- Rintatolimod
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- AIM ImmunoTech Inc.
Pancreatic Cancer, Stage IV Pancreatic Cancer
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
- Trial name
- NCT02005315
- Testing
- Vantictumab, Nab-Paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.